Tiger Pharmaceuticals (03347) issued an announcement. On March 28, 2024, the 6th meeting of the 5th board of directors of the company and...
Zhitong Finance App News, Tiger Pharmaceuticals (03347) issued an announcement. On March 28, 2024, the 6th meeting of the 5th board of directors of the company and the fourth meeting of the 5th board of supervisors deliberated and passed the “Proposal on Terminating the Implementation of the 2022 A-share Restricted Stock Incentive Plan and Abolish Restricted Shares”, and decided to stop implementing the 2022 A-share Restricted Stock Incentive Plan. All restricted stocks granted but not yet owned were abolished. The “Company's 2022 A-share Restricted Stock Incentive Plan Implementation and Assessment Management Measures” and other related documents were also terminated .
The company's 7.4697 million shares used to implement employee stock ownership plans or equity incentive plans were not used in the two aforementioned repurchases. According to the company's share repurchase plan and the relevant provisions of the “Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 9 - Share Repurchase”, since the shares repurchased by the company are not expected to be used to implement share incentives or employee stock ownership plans, the company plans to cancel the 7.4697 million shares held in the special repurchase account and reduce the company's registered capital accordingly.